Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Romidepsin antagonism with CHOEP

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Data availability

Raw data were generated at the University of Texas MD Anderson Cancer Center. Derived data supporting the findings of this study are available from the corresponding author JLR upon reasonable request.


  1. Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai SV, et al. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study. Leukemia. 2023;37:433–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bachy E, Camus V, Thieblemont C, Sibon, D, Casasnovas, R, Ysebaert, L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: Results of the Ro-CHOP Phase III study (Conducted by LYSA). J Clin Oncol. 2021.

  3. Valdez BC, Li Y, Murray D, Brammer J, Liu Y, Hosing C, et al. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 2016;7:63829–38.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharm Sci. 2006;27:438–46.

    Article  CAS  PubMed  Google Scholar 

  5. Valdez BC, Hassan M, Andersson BS. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Exp Hematol. 2017;52:65–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations



JLR, BSA, and YN contributed to writing in each section of the article. BV and BSA have made a substantial contribution to the concept and design of the article and research models in the laboratory.

Corresponding author

Correspondence to J. L. Ramdial.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ramdial, J.L., Valdez, B.C., Andersson, B.S. et al. Romidepsin antagonism with CHOEP. Leukemia (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI:


Quick links